Ariquet has unique receptor-binding profile that helps improve both positive and negative symptoms while supporting mood stabilization. The availability of 25 mg, 50 mg ER, and 100 mg strengths allows flexible dose titration according to individual patient needs. Ariquet – Rational Choice for the Treatment of Bipolar Disorder and Schizophrenia.
Ariquet (Quetiapine) works by modulating multiple neurotransmitter pathways, including dopamine and serotonin receptors, Quetiapine helps restore emotional balance, reduce psychotic symptoms, and improve overall functional outcomes.
Ariquet (Quetiapine) offers effective management of bipolar disorder and Schizophrenia with a comparatively lower risk of Extrapyramidal symptoms (EPS) than conventional antipsychotics, making it a rational treatment choice
Ariquet 25: Each film coated tablet contains Quetiapine Fumarate USP equivalent to Quetiapine 25 mg.
Ariquet 50 ER: Each extended-release film coated tablet contains Quetiapine Fumarate USP equivalent to Quetiapine 50 mg.
Ariquet 100: Each film coated tablet contains Quetiapine Fumarate USP equivalent to Quetiapine 100 mg.
Quetiapine Fumarate is indicated for the treatment of Bipolar Disorder & Schizophrenia.
Quetiapine Fumarate can be taken with or without food as per following:
| Indication | Initial Dose | Recommended Dose/ Dose Range |
| Schizophrenia-Adults | 25 mg twice daily | 150-750 mg/day |
| Schizophrenia-Adoles- cents (13 to 17 years) | 25 mg twice daily | 400-800 mg/day |
| Bipolar Mania - Adults (Monotherapy or as an adjunct to lithium or divalproex) | 50 mg twice daily | 400-800 mg/day |
| Bipolar Mania - Children and Adolescents (10-17 years), Monotherapy | 25 mg twice daily | 400-600 mg/day |
| Bipolar Depression - Adults | 50 mg once daily (at bedtime) | 300 mg/day |
| Bipolar I Disorder Maintenance Therapy - Adults | Administer twice daily totaling 400-800 mg/day as adjunct to lithium or divalproex. Generally, in the maintenance phase, patients continued on the same dose on which they were stabilized. |
Use of quetiapine is not recommended for patients who have shown a hypersensitivity to the drug or its ingredients.
If signs and symptoms of Neuroleptic malignant syndrome, tardive dyskinesia, low blood pressure, fainting (especially during initial dose titration period) appear, dose reduction or discontinuation of Quetiapine should be considered. Perform eye exams before starting and every 6 months; stop if significant lens changes occur. Use cautiously in patients with seizures, thyroid disorders, high prolactin, liver/kidney disease, heart disease, blood sugar issues, or temperature regulation problems.
There is no specific antidote to Quetiapine. In cases of severe intoxication, the possibility of multiple drug involvement should be considered, and intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system and close medical supervision and monitoring should continue until the patient recovers.
Somnolence, dizziness, dry mouth, constipation, dyspepsia, postural hypotension, elevated ALT (SGPT) levels, weight gain.
Caution should be exercised when Quetiapine is used concomitantly with medicines known to cause electrolyte imbalance or to increase QT interval. Co-administration of Quetiapine and thioridazine or carbamazepine caused increases in the clearance of Quetiapine. Co-administration of Quetiapine with another microsomal enzyme inducer, phenytoin, also caused increases in the clearance of Quetiapine.
Pregnancy: Quetiapine should be used only if the potential benefit justifies the potential risk. Lactation: It is recommended that women receiving Quetiapine should not breast feed. In children: Safety and effectiveness have only been established for schizophrenia in adolescent patients 13 to 17 years of age and in bipolar mania in children and adolescent patients 10 to 17 years of age. In geriatric patients: A lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period should be considered. Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed.
Ariquet 25: Each box contains 50 tablets in alu-alu blister pack.
Ariquet 50 ER: Each box contains 50 tablets in alu-alu blister pack.
Ariquet 100: Each box contains 30 tablets in alu-alu blister pack.
FR
DE